Ipamorelin + Tesamorelin dosing — the commonly cited blend approach

This product combines two growth-hormone peptides that act on different receptors: tesamorelin is a GHRH analog, and ipamorelin acts on the ghrelin receptor. The idea behind the blend is complementary, dual-pathway GH stimulation. Because there are no trials of the combination, any "dose" is reasoned from the individual components rather than validated.

Community discussion generally treats each component separately and combines them. These numbers are anecdotal and not medically established:

• Ipamorelin: commonly cited around ~100 mcg per injection (sometimes up to ~200–300 mcg), typically 1–3 times per day.
• Tesamorelin: commonly cited around ~1–2 mg per day (the FDA-approved tesamorelin product for HIV-associated lipodystrophy uses 2 mg once daily, which is where the upper figure comes from).
• Because the two are blended in one vial, each component's concentration has to be tracked separately, and the ratio is a formulation choice, not a validated standard.

Starting low and assessing tolerance is the usual community framing.

Both peptides are injected subcutaneously from a reconstituted powder, since they are broken down if swallowed.

• The delivered amount of each depends on reconstitution and on reading syringe units correctly — with a blend, that math is easy to get wrong.
• Timing is often aligned with sleep or training to match natural GH pulses; sterility and cold storage are emphasized.

There is no regulator-approved combination framework with defined indications, contraindications, or monitoring for this blend. A clinician can account for the two agents, monitor GH and IGF-1 effects, and recognize when raising GH could be harmful. The commonly cited numbers are educational context, not a validated protocol.